[The liver concentration of cephradin and cephacetril and their elimination in the bile].
Liver biopsies and serum samples were collected after intravenous application of 2 g cephradin (n = 13) or 2 g cephacetril (n = 11) during surgery. There was no difference in the serum levels of cephradin and cephacetril. 30 min. after i.v. application of cephradin the liver tissue concentration was 72.62 mcg/g. 30 min. after i.v. cephacetril the liver tissue concentration was 5.83 mcg/g. The quotient of liver tissue concentration to serum concentration for cephradin was between 0.36 and 0.83, and for cephacetril between 0.02 and 0.16. The excretion of cephradin and cephacetril in human bile was studied by collecting bile samples from the common bile duct via T-tube drainage (n = 17). Cholecystomized patients were given 2 g of antibiotics intravenously. Serum levels of cephradin were 263 mcg/ml 5 min after application, and 22 mcg/ml after 240 min. Serum levels of cephradin were 263 mcg/ml 5 min after application, and 22 mcg/ml after 240 min. Serum levels of cephacetril were 193 mcg/ml 5 min after application, and 27 mcg/ml after 240 min. The highest levels of cephradin in the bile were found 75 min after injection at a concentration of 86.4 mcg/ml; the highest level for cephacetril was 21.8 mcg/ml at 15 min. In patients with hyperbilirubinaemia cephradin reached a mean maximum concentration of 29.6 mcg/ml in bile samples, in comparison to 117.4 mcg/ml in normal patients, while no difference was seen with cephacetril. After intravenous administration of 2 g cephradin biliary concentration are achieved which may be sufficiently high to be effective not only against the very sensitive gram-positive organisms, but also against most strains of E. coli, Klebsiella and indol-negative Proteus. Cephradin is effective in the treatment of cholangitis and intrahepatic abscesses, as was observed in 18 patients. A free bile-flow is essential.
D001646:Bile / Q000032:analysis*; D002505:Cephacetrile / Q000032:analysis* / Q000378:metabolism; D002511:Cephalosporins / Q000032:analysis*; D002515:Cephradine / Q000032:analysis* / Q000378:metabolism / Q000627:therapeutic use; D002761:Cholangitis / Q000188:drug therapy; D002763:Cholecystectomy; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D006932:Hyperbilirubinemia / Q000378:metabolism; D007709:Klebsiella / Q000187:drug effects; D008099:Liver / Q000032:analysis*; D008100:Liver Abscess / Q000188:drug therapy; D011511:Proteus / Q000187:drug effects
D002511:Cephalosporins; D002515:Cephradine; D002505:Cephacetrile
Die Lebergewebekonzentration von Cephradin und Cephacetril sowie deren Gallenausscheidung